NOTICE OF MEETING AND AGENDA

Public Board Meeting
July 30 and 31, 2014

Contact Person: Laura Hendricks
(916) 574-7918

This board meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Laura Hendricks at (916) 574-7918, by emailing laura.hendricks@dca.ca.gov or sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

DATE: July 30 and 31, 2014

PLACE: Department of Consumer Affairs
First Floor Hearing Room
1625 North Market Blvd
Sacramento, CA 95834

WEBCAST: http://www.pharmacy.ca.gov/meetings/current_webcasts.shtml
(Link to Webcast will not be available until 9 a.m. on July 30, 2014)

NOTE: Pharmacists and pharmacy technicians who attend in person this Board Meeting may be awarded 6 hours of CE, in accordance with the board’s CE policy. Sign in and sign out that day are required for the CE credit.

Additionally pharmacists who wish to register with CURES may do so at this meeting by following the CURES Registration Information sheet that follows as the last page of this agenda. Registration will be open from 9:00 a.m.-11:30 a.m. on July 30th and 31st.

For verification of the meeting, call (916) 574-7918 or (916) 574-7900 or access the board’s Web site at www.pharmacy.ca.gov.

Meeting Materials should be available on the board’s Web site at www.pharmacy.ca.gov by July 25, 2014.
AGENDA

Wednesday, July 30, 2014

Call to Order 9:00 a.m.

I. GENERAL ANNOUNCEMENTS AND OVERVIEW OF CURES REGISTRATION PROCEDURES FOR BOARD OF PHARMACY

II. APPROVAL OF THE FULL BOARD MEETING MINUTES OF APRIL 23-24, 2014

III. APPROVAL OF THE FULL BOARD MEETING MINUTES OF JUNE 26, 2014

IV. PUBLIC COMMENT ON ITEMS NOT ON THE AGENDA/AGENDA ITEMS FOR FUTURE MEETINGS

   Note: The board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code Sections 11125, 11125.7(a)]

V. RECOGNITION AND CELEBRATION OF PHARMACISTS LICENSED FOR 50 YEARS IN CALIFORNIA

VI. PRESENTATION BY DEBBIE BARROW, PHARMD, ON STERILE COMPOUNDING IN A SMALL HOSPITAL PHARMACY

VII. RESULTS OF BOARD OF PHARMACY INSPECTIONS OF STERILE COMPOUNDING PHARMACIES AND IMPLEMENTATION OF SENATE BILL 294 (EMMERSON, CHAPTER 565, STATUTES OF 2013)

VIII. DISCUSSION AND POSSIBLE ACTION TO INITIATE RULEMAKING TO ADOPT PROPOSED TEXT AT 16 CALIFORNIA CODE OF REGULATIONS SECTION 7135 ET SEQ, AN 1751 ET SEQ. RELATING TO PHARMACY COMPOUNDING

IX. LUNCH

   A lunch break will be taken at some point during the day’s meeting.

X. LICENSING COMMITTEE REPORT

   Report of the Meeting Held June 18, 2014. Note: Several items from the June 18, 2014 Licensing Committee Meeting were heard during the Board of Pharmacy Meeting convened June 26, 2014.

   a. Discussion on Possible Development of a Policy Statement related to the Sale of Tobacco Products from Pharmacies, Pursuant to a Request from Pharmacists Planning Services, Incorporated
   b. Presentation on the Results of Continuing Education Audits of Pharmacists in California
   c. Discussion on Reporting of Intern Hours Earned for Interns in ACPE Accredited Schools
   d. Review and Discussion of Questions on Applications to Collect Prior Conviction Information
   e. Competency Committee Report
      1. Recruitment of New Members for the Board’s Competency Committee
2. Job Analysis Design of the California Pharmacist Practice for the Practice Standards and Jurisprudence Examination (CPJE) for 2015-2020
f. Licensing Statistics (July 1, 2014 – June 30, 2014)
g. Fourth Quarterly Report on the Committee’s Goals for 2013/14

XI. LEGISLATION AND REGULATION COMMITTEE
Note: There has been no meeting of the Legislation and Regulation Committee since April 2014.

Part 1: Legislation Report
   1. SB 960 (Morrell) Pharmacy Licenses: Letters of Admonishment
   2. SB 1466 (Committee on Business, Professions, and Economic Development) Omnibus Provision Relating to Requirements for a Designated Representative
   3. SB 600 (Lieu) Repeal of Pedigree Requirements
   4. AB 2605 (Bonilla) Requirements for Third Party Logistics Providers
b. Legislation Impacting the Practice of Pharmacy or the Board’s Jurisdiction
   1. AB 186 (Maienschein) Professions and vocations: military spouses: temporary licenses
   2. AB 1535 (Bloom) Pharmacists: naloxone hydrochloride
   3. AB 1702 (Maienschein) Professions and vocations: incarceration
   4. AB 1727 (Rodriguez) Prescription Drugs: collection and distribution program
   5. AB 1841 (Mullin) Medical assistants
   6. AB 2396 (Bonta) Convictions: expungement: licenses
   7. AB 2603 (V. Manuel Perez) Controlled Substances: permissive lawful possession
   8. AB 2757 (Bocanegra) Centralized hospital packaging pharmacies: medication labels
   9. SB 1014 (Jackson) Pharmaceutical waste: home generated
   10. SB 1039 (Hernandez) Pharmacies: furnishing drugs
   11. SB 1258 (DeSaulnier) Controlled substances: prescriptions: reporting
c. Other Legislation Being Tracked by Board Staff
   1. AB 1743 (Ting) Hypodermic needles and syringes
   2. AB 2147 (Melendez) State government Internet Web site: information practices
   3. AB 2418 (Bonilla) Health care coverage: prescription drug refills
   4. AB 2058 (Wilk) Open Meetings

Part 2: Regulation Report
a. Board-Approved – Undergoing Administrative Review
   Update on Rulemaking to Amend Section 1707.5 of Title 16 California Code of Regulations Regarding Patient-Centered Labeling Requirements
b. Board-Approved – Awaiting Notice
   1. Combined Rulemaking – Proposal to Amend Title 16 California Code of Regulations Sections 1702, 1702.1, 1702.2 and 1702.5 Related to Renewal Requirements
2. Combined Rulemaking – Proposal to Amend Title 16 California Code of Regulations Sections 1732.05, 1732.2, and 1732.5 related to Continuing Education
3. Proposal to Amend Title 16 California Code of Regulations Section 1703 Related to “Section 100” Regulatory Actions

XII. PRESCRIPTION MEDICATION ABUSE SUBCOMMITTEE

1. Update on Review of Prescription Drug Abuse Materials Currently Available on the Board of Pharmacy’s Website.
2. Summary of Presentation on Prescription Drug Abuse Prevention Materials by Rabia Atayee, PharmD, Assistant Profession of Clinical Pharmacy, UCSD School of Pharmacy; and Nathan Painter, PharmD, Associate Clinical Professor, UCSD School of Pharmacy
3. Review of Educational Curriculum Materials for Teachers Developed by Purdue Pharma
4. Summary of Discussion About Use of/Education About Naloxone as Overdose Antidote
5. Summary of CURES Data Report of Controlled Substances Dispensed in California
6. Summary of Results of DEA’s April 2014 National Drug Take Back Day
7. Summary of Report of the Medical Board of California’s Prescribing Task Force
8. Summary of Review of the Medical Board of California’s Public Service Announcement Developed for Prescription Drug Abuse Awareness Month
9. Summary of Review and Discussion of Articles Documenting the Issues of Prescription Medication Abuse
10. Update on Public Outreach to Address Prescription Drug Abuse

XIII. SB 493 IMPLEMENTATION COMMITTEE

1. Summary of Elements of SB 493 (Hernandez, Chapter 469, Statutes of 2013)
2. Overview of Use of “Advanced Practice Pharmacists” in Other States
3. Summary of Identification of Materials Where Board Guidance is Envisioned, Discussion of the Requirements:
   a. For Pharmacists Who Initiate and Administer Immunizations Pursuant to Recommended Immunization Schedules by the Federal Advisory Committee of Immunization Practices
   b. For Prescription Medications not Requiring a Diagnosis that are Recommended by the CDC for Travel Outside the US
   c. For Ordering and Interpreting Tests to Monitor and Manage Drug Therapies
5. Summary of Discussion on the Requirements for Pharmacists Who Furnish Nicotine Replacement Products and Development of Draft Protocols
6. Summary of Discussion on Application Requirements of the Advanced Practice Pharmacist License  
   a. Board of Pharmacy Specialties Certification Programs  
   b. Other Certification Programs (e.g., Commission for Certification in Geriatric Pharmacy)  
   c. Other Programs Envisioned or Under Development  
7. Updated on the Development of Elements of Other Certification Programs  
8. Summary of Discussion on Renewal Requirements of the Advanced Practice Pharmacist License  
   a. For Pharmacists who Initiate and Administer Immunizations Pursuant to Recommended Immunization Schedules by the Federal Advisory Committee of Immunization Practices  
   b. For Prescription Medications not Requiring a Diagnosis that are Recommended by the CDC for Travel Outside the US  
   c. For Ordering and Interpreting Tests to Monitor and Manage Drug Therapies  

XIV. ENFORCEMENT AND COMPOUNDING COMMITTEE  
Note: There has been no meeting of the Enforcement and Compounding Committee since the April 23-24, 2014 Board Meeting.  
1. Future Committee Meeting Dates  
2. Fourth Quarterly Report on the Committee’s Goals for 2013/14  
4. Three Year Comparison of Enforcement Statistics  

XV. COMMUNICATION AND PUBLIC EDUCATION COMMITTEE  
Note: There has been no meeting of the Communication and Public Education Committee since the April 23-24, 2014 Board meeting.  
1. Future Committee Meeting Dates  
2. Update on Outreach Activities  

XVI. Discussion and Possible Action on Requests for Waiver of California Business and Professions Code Section 4118 Pertaining to Licensure as a Centralized Hospital Packaging Pharmacy, California Business and Professions Code Sections 4128 et seq., From Loma Linda University Medical Center  

XVII. Discussion and Possible Action on a Request from Keck Graduate Institute School of Pharmacy for Recognition by the Board Under Section 16 CCR Section 1719 for Purposes of issuing Intern Licenses  

ADJOURNMENT FOR THE DAY
Thursday, July 31, 2014

RESUMPTION OF OPEN SESSION 8:30 a.m.

XVIII. ORGANIZATIONAL DEVELOPMENT COMMITTEE

Note: There has been no formal meeting of the organizational development committee since the April 23-24, 2014 Board Meeting, however several ad hoc teleconference meetings were convened to discuss items that required immediate attention.

1. Future Board Meeting Dates
2. Budget Update/Report
   b. Budget Report for 2013/2014
   c. Fund Condition Report
   d. Update on BreEZe, DCA’s New Computer System
   e. Board Member Reimbursement and Mail Vote Information
3. Personnel Update
   a. Board Member Update
   b. Board Staff Update
4. Review of Board Comments Submitted on a Proposed Federal Rescheduling of Hydrocone From Schedule III to Schedule II

XIX. EXECUTIVE OFFICER’S REPORT

1. Update on the Activities of the Medical Board of California by Executive Director Kimberly Kirchmeyer
2. Formation of the California Department of Public Health’s Opioid Overdose Work Group
3. Report on the Federal Department of Health and Human Services’ Advancing Policy and Practice: A 50 State Working Meeting to Prevent Opioid-Related Overdose
4. A Six-Hour CE Program is Planned For September 3 in Santa Barbara on Prescription Drug Abuse, Corresponding Responsibility and Preventing Pharmacy Thefts, which will be co-sponsored by the Los Angeles Office of the Federal Drug Enforcement Administration
5. Information on the Development of Corresponding Responsibility Brochure

XX. FORUM OF PATIENT-CENTERED PRESCRIPTION LABELS

At the conclusion of the Executive Officer’s Report, the remainder of the board meeting will be dedicated to an informational forum on Patient-Centered Prescription Labels. The board will review its regulation requirements for patient-centered labels. It will examine standards for patient-centered labels developed by various groups. It will review data and surveys collected by the board. The board will hear presentations from invited speakers and the public on patient-centered prescription labels. Finally the board will review the elements of the regulation and consider possible modifications to regulation requirements.